Bandingkan Harga & Kinerja Prodia Diagnostic Line Tbk (PRDL) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Prodia Diagnostic Line Tbk dan Organon Pharma Indonesia Tbk.: Prodia Diagnostic Line Tbk diperdagangkan di Rp236 (kapitalisasi pasar 428,75 M, volume 24 jam 13,83 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Prodia Diagnostic Line Tbk jauh lebih besar — sekitar 4,1× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| PRDL | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 428,75 M | 104,4 M |
Volume | 13,83 jt | — |
Lot | 138,27 rb | — |
Perputaran | 3,27 M | — |
Harga Rata-rata | 236,62 | — |
Nilai Transaksi | 3,27 M | — |
Harga Ekuilibrium Indikatif | 236 | — |
Volume Ekuilibrium Indikatif | 1,74 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Prodia Diagnostic Line Tbk
PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Selengkapnya di halaman PRDL →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
